Moderna Target of Unusually Large Options Trading (NASDAQ:MRNA)

This post was originally published on this site

Moderna, Inc. (NASDAQ:MRNAGet Rating) was the recipient of some unusual options trading on Wednesday. Traders acquired 52,367 call options on the company. This represents an increase of 15% compared to the average daily volume of 45,358 call options.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Morgan Stanley dropped their price target on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. SVB Leerink lifted their price target on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday. Finally, Piper Sandler dropped their price target on Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $226.92.

Insider Buying and Selling at Moderna

In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $156.73, for a total value of $6,269,200.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $848,214,296.58. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, President Stephen Hoge sold 234 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $133.71, for a total value of $31,288.14. Following the completion of the sale, the president now directly owns 1,622,820 shares of the company’s stock, valued at $216,987,262.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $156.73, for a total value of $6,269,200.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $848,214,296.58. The disclosure for this sale can be found here. Insiders sold a total of 554,029 shares of company stock worth $82,263,545 over the last ninety days. 17.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP grew its position in Moderna by 3.5% during the 2nd quarter. Allworth Financial LP now owns 1,780 shares of the company’s stock worth $254,000 after acquiring an additional 60 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Moderna by 20.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 371 shares of the company’s stock worth $53,000 after acquiring an additional 62 shares during the last quarter. AlphaMark Advisors LLC grew its position in Moderna by 18.2% during the 4th quarter. AlphaMark Advisors LLC now owns 415 shares of the company’s stock worth $105,000 after acquiring an additional 64 shares during the last quarter. PFG Private Wealth Management LLC grew its position in shares of Moderna by 4.5% in the 2nd quarter. PFG Private Wealth Management LLC now owns 1,547 shares of the company’s stock valued at $221,000 after buying an additional 66 shares during the last quarter. Finally, Kalos Management Inc. grew its position in shares of Moderna by 7.9% in the 4th quarter. Kalos Management Inc. now owns 927 shares of the company’s stock valued at $219,000 after buying an additional 68 shares during the last quarter. Institutional investors own 61.20% of the company’s stock.

Moderna Trading Up 4.1 %

Shares of MRNA opened at $194.18 on Friday. Moderna has a 52-week low of $115.61 and a 52-week high of $497.49. The business’s fifty day moving average is $151.55 and its 200-day moving average is $152.84. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. The firm has a market cap of $77.24 billion, a price-to-earnings ratio of 5.71, a PEG ratio of 0.91 and a beta of 1.61.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. The business had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. Moderna had a return on equity of 121.86% and a net margin of 64.77%. Moderna’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.46 EPS. Equities analysts anticipate that Moderna will post 27.16 EPS for the current fiscal year.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Stories

Receive News & Ratings for Moderna Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Moderna and related companies with MarketBeat.com’s FREE daily email newsletter.